Barclays PLC Avenue Therapeutics, Inc. Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.88 - $1.78 $990 - $2,002	-1,125 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$1.48 - $2.65 $1,410 - $2,525	-953 Reduced 45.86%	1,125 $2,000
Q2 2021 Aug 13, 2021	SELL	$2.41 - $7.11 $8,410 - $24,813	-3,490 Reduced 62.68%	2,078 $5,000
Q1 2021 May 13, 2021	BUY	$4.7 - $7.17 $16,064 - $24,507	3,418 Added 158.98%	5,568 $34,000
Q4 2020 Feb 11, 2021	SELL	$2.95 - $11.04 $2,560 - $9,582	-868 Reduced 28.76%	2,150 $13,000

Q3 2020 Nov 12, 2020	SELL	$9.37 - $12.06 $5,687 - $7,320	-607 Reduced 16.74%	3,018 $33,000
Q2 2020 Aug 12, 2020	BUY	$8.29 - $11.47 $30,051 - $41,578	3,625 New	3,625 $39,000
Q4 2019 Feb 10, 2020	SELL	$5.26 - $9.6 $57 - $105	-11 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.58 - $6.3 $61 - $69	11 New	11 $0
Q2 2019 Aug 14, 2019	SELL	$4.33 - $6.54 $173 - $261	-40 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$4.75 - $6.59 $190 - $263	40 New	40 $0

Ticker ATXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,127,720
Market Cap $13.8M
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.